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Unraveling Myths of Platelet
Function and Genetic Testing
The Road to Making Tailored
Antiplatelet Therapy a Reality*
Dominick J. Angiolillo, MD, PHD
Jacksonville, Florida
Clopidogrel therapy is associated with a broad variability in
pharmacodynamic (PD) response, and individuals with high
on-treatment platelet reactivity (HPR) have an increased
risk of recurrent ischemic events, including stent thrombosis
(1,2). Given the pivotal role of this platelet-inhibiting
strategy in patients with acute coronary syndrome and
undergoing percutaneous coronary interventions (PCIs),
numerous investigations have been conducted to identify
determinants of HPR as well as cutoff values with the most
meaningful prognostic implications (1,2). Recent studies
have identified genetic determinants to significantly modu-
late PD response to clopidogrel and influence clinical
outcomes (3). However, what is the additive value of
individual’s unmodifiable genetic makeup to a “moving
target” such as platelet reactivity remains unknown. Indeed,
a better understanding of this and other facets of platelet
function and genetic testing may provide additional re-
sources to better risk stratify acute coronary syndrome/PCI
patients and potentially set the basis for tailored antiplatelet
treatment strategies in high-risk settings with the goal of
improving clinical outcomes (4).
See page 2474
In this issue of the Journal, Campo et al. (5) investigated
rofiles of on-treatment platelet reactivity over time and
heir relationships with genetic polymorphisms modulating
lopidogrel response and clinical outcomes at 1-year in
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studied, and PD testing by means of the point-of-care
VerifyNow P2Y12 platelet function assay (Accumetrics
Inc., San Diego, California) was conducted at 3 time points
(before PCI, and 1 and 6 months after). Genetic determi-
nants included the cytochrome P450 (CYP) 2C19*2, *17,
CYP3A5*3, and ABCB1 polymorphisms. On-treatment
platelet reactivity varied in over one-quarter of patients
(27.6%) during the first month after PCI, with most of
these attributed to subjects initially coined as “poor respond-
ers” at the time of PCI, who subsequently became “respond-
ers” at 1 month. Genotypes explained to a certain extent
(18%) such variation. CYP2C19*2 and *17 polymorphisms
had consistent effects on PD measures, whereas ABCB1 was
more influential at baseline. On-treatment platelet reactivity
was subject to minor variations after 1 month. Importantly,
the serial PD evaluations determined that values of on-
treatment platelet reactivity assessed at 1 month had the
best prognostic value on ischemic and bleeding events.
These assessments also enabled the definition of a “thera-
peutic window” of on-treatment platelet reactivity offering
the best balance between safety and efficacy. Ultimately, the
clustering of PD, genetic, and clinical information gathered
from this analysis allowed the generation of a scoring system
to predict HPR prognosis at 1 month and 1 year. Relevant
information emerges from the present investigation that
provides new and important insights in the field of platelet
function and genetic testing among patients undergoing
PCI that merit being emphasized.
The optimal timing of platelet function testing to predict
outcomes has been a topic of debate. To date, studies have
been focused on functional testing in the peri-PCI period
(1,2). Indeed, knowing the results of platelet function
testing before hospital discharge is more practical for the
clinician, as this would potentially enable risk stratifying
patients early on. However, an inferior prognostic value of a
PD measure assessed in the peri-PCI period compared with
that assessed at a different time point can translate into a
limited benefit if a tailored treatment strategy were to be
applied. The serial PD assessments conducted in the present
investigation demonstrate that a considerable number of
patients undergoing PCI treated with a commonly used
clopidogrel dosing regimen (600-mg loading dose/75-mg
maintenance dose) may be considered poor responders if
testing is performed in the peri-PCI period, a finding that is
in line with earlier investigations (6). The observation that
functional assessments performed at 1-month follow-up
more reliably reflect the true status of on-treatment platelet
reactivity of a patient is also supported by its better prog-
nostic value. These results are in line and may have had in
part a contributing role to the neutral findings from the
GRAVITAS (Gauging Responsiveness With a VerifyNow
Assay–Impact on Thrombosis and Safety) trial (7), which
failed to show any differences in 6-month outcomes in
patients with HPR randomized to standard- or high-
v
V
t
(
c
c
i
P
d
a
e
w
p
c
p
t
d
i
o
o
h
i
p
a
i
(
m
l
u
p
(
a
a
i
e
M
m
a
d
p
a
t
m
p
t
(
w
i
i
p
t
l
P
g
m
f
w
c
(
a
f
h
t
H
c
r
a
w
c
v
i
p
t
a
2485JACC Vol. 57, No. 25, 2011 Angiolillo
June 21, 2011:2484–6 Platelet Function and Genetic Testingmaintenance dose of clopidogrel. In this trial, platelet
reactivity was defined 12 to 24 h after PCI and notably,
approximately 40% of poor-responder patients randomized
to a standard clopidogrel regimen became responders at 1
month. Such change in response status may be attributed to
confounding factors occurring in the peri-PCI period.
Overall, these observations lead to concerns on the value of
platelet function testing if performed in the peri-PCI period
as well as the practicality of applying platelet function
testing in clinical practice given that assessments conducted
after hospital discharge, particularly if after 1 month, would
have less likelihood of being performed on a broad scale.
Indeed, future investigations are warranted to better under-
stand if a narrower time frame following PCI can be
identified to minimize false-positive connotations of poor-
responder status. In addition, prompt identification of true
poor responders is also important, given the higher risk of
recurrent events in the earlier phases after PCI.
Cutoff values of on-treatment platelet reactivity that
should be applied to define response status have also been
subject to numerous controversies. This applies particularly
to point-of-care testing devices, given that these represent
the only hope for a broad-based application of platelet
function testing in daily clinical practice as other assess-
ments using light transmittance aggregometry or flow cy-
tometry are not available in most cardiac catheterization
laboratories (4). Using the VerifyNow point-of-care assay,
many studies have identified P2Y12 reactivity unit cutoff
alues of 230 to 240 to have the best prognostic values.
erifyNow was also used to define HPR in the GRAVITAS
rial (1,7). However, the present analysis from Campo et al.
5) identified a slightly lower cutoff value, which was
onsistent with other studies (8). In line with this, a lower
utoff value for tailoring antiplatelet therapy was being used
n the TRIGGER-PCI (Testing Platelet Reactivity in
atients Undergoing Elective Stent Placement on Clopi-
ogrel to Guide Alternative Therapy With Prasugrel) trial
ssessing clinical outcomes in HPR patients undergoing
lective PCI randomized to prasugrel or clopidogrel, which
as recently halted due to the low rates of events. Indeed,
atient selection, in addition to timing of assessment, can
ontribute to levels of platelet reactivity with different
rognostic implications (9). These observations underscore
hat cutoff values to define patients with HPR are still not
efinitive and highlight the importance of pursuing further
nvestigations to define the prognostic significance of levels
f platelet reactivity according to a given clinical setting.
Furthermore, it should be kept in mind that the spectrum
f response variability also denotes that certain patients may
ave “low” on-treatment platelet reactivity, which may
ncrease their potential for bleeding events. Contrary to the
lethora of information on the association between HPR
nd ischemic events, there is limited data on the prognostic
mplications, namely bleeding, of low platelet reactivity
10). Importantly, bleeding complications are not trivial and
ay carry the same weight or even more on predictingong-term mortality than a recurrent myocardial infarction,
nderscoring the importance of also defining levels of
latelet reactivity below which this complication may occur
11). The present study was able to determine such a level
nd defined a “therapeutic window,” using the VerifyNow
ssay, that delineates levels of on-treatment platelet reactiv-
ty associated with the lowest risk of ischemic and bleeding
vents. This had been previously determined with the
ultiplate Assay (Verum Diagnostica, Munich, Ger-
any) (12). Indeed, larger studies are needed to provide
better determination of the optimal cutoff values
efining such a therapeutic window, as well as their
rognostic value, which may potentially vary according to
specific clinical setting, thus enhancing the promises for
ailored antiplatelet therapy.
The ever-increasing data on the impact of genetic deter-
inants on platelet reactivity and clinical outcomes have
rompted several considerations on the use of genetic
esting to risk stratify patients and tailor antiplatelet therapy
13). Indeed, the unalterable status of our genetic patrimony
ould overcome the issues surrounding the inter- and
ntrapatient variability of PD measures. However, it is
mportant to underscore that genotypes may be of limited
rognostic value, as they contribute only to a small extent to
he platelet phenotype and clinical outcomes (14). This
eads to question if genotypes can be of adjunctive value to
D testing in risk stratifying patients. The present investi-
ation supports that genetic and platelet function testing
ay represent complementary tools. Further, when results
rom platelet function tests and genetic tests are combined
ith a simple clinical parameter represented by creatinine
learance, also a marker associated with platelet reactivity
15), the investigators were able to generate a risk score
lgorithm to predict HPR prognosis at 1-month and 1-year
ollow-up. The observation that only creatinine clearance
ad additive value to the scoring system may be related to
he fact that this overlaps with other clinical conditions.
owever, the small sample of the study not allowing other
linical factors to emerge as independent predictors may
epresent a more reliable explanation; therefore, the scoring
lgorithm generated from this study needs to be interpreted
ith caution. Indeed, larger datasets are warranted to more
omprehensively generate scoring systems, as well as to
alidate them. Despite these limitations, this study provides
mportant insights to help unravel some of the myths of
latelet function and genetic testing and offers the premises
o endure further investigations necessary to make tailoring
ntiplatelet therapy a reality.
Reprint requests and correspondence: Dr. Dominick J. Angio-
lillo, University of Florida College of Medicine-Jacksonville, 655
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